Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simmitinib plus Irinotecan Liposome in Advanced Esophageal Squamous Cell Carcinoma
NCT06512428Phase 2Recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cimetinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd.. Started Mar 2024; status: recruiting.
02
Drugs
Cimetinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06512428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512428.